10.5 m capital raising, page-8

I don't think anyone associated with the company is expectng a faliure with the present trials of AOD9604, and I beleive that the progress of the 2A trials of ACV1 have had obvious success even at this stage. After all, you give somebody in pain an affective pain drug, they'll tell you in five minutes if it worked.

I think that the company is looking at success on both fronts (AOD9604 and ACV1) and wants to be well funded to push hard on the heels of the upcoming results.

To be clear, I mean to push both drugs even if there is no licensing deal immediately on the books.

Keep in mind that if AOD9604 comes in strong, MBP will push the goalposts for a bigger slice in any deal. Meanwhile, the delays in getting this drug to market have already been too prolonged. They won't wnat to keep things dialled back while they spend six months to a year negotiating details of a deal.